U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H18FN7
Molecular Weight 399.4236
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VACTOSERTIB

SMILES

CC1=CC=CC(=N1)C2=C(N=C(CNC3=CC=CC=C3F)N2)C4=CN5N=CN=C5C=C4

InChI

InChIKey=FJCDSQATIJKQKA-UHFFFAOYSA-N
InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)

HIDE SMILES / InChI

Molecular Formula C22H18FN7
Molecular Weight 399.4236
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800040770 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/35df583a06ef378df8540f6db2d36534.html

EW-7197 is an orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity. EW-7197 is in phase I clinical trials for the treatment of solid tumors. Also, EW-7197 has a strong potential as an anti-fibrosis therapeutic agent.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.31 μg/mL
340 mg 1 times / day single, oral
dose: 340 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VACTOSERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.05 μg/mL
340 mg 1 times / day multiple, oral
dose: 340 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VACTOSERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.29 μg × h/mL
340 mg 1 times / day single, oral
dose: 340 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VACTOSERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8.02 μg × h/mL
340 mg 1 times / day multiple, oral
dose: 340 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VACTOSERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.9 h
340 mg 1 times / day single, oral
dose: 340 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VACTOSERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.4 h
340 mg 1 times / day multiple, oral
dose: 340 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VACTOSERTIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
340 mg 1 times / day multiple, oral
Highest studied dose
Dose: 340 mg, 1 times / day
Route: oral
Route: multiple
Dose: 340 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: cancer
Sex: M+F
Food Status: FASTED
Population Size: 4
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
2014 May 22
Patents

Patents

Sample Use Guides

Starting single daily dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm (once daily for 5 days followed by 2 days without treatment in 28-day cycles)
Route of Administration: Oral
EW-7197 inhibited 4T1 cell proliferation when added at a high concentration (5,000 nM/L)
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:23:48 GMT 2023
Edited
by admin
on Sat Dec 16 08:23:48 GMT 2023
Record UNII
6T4O391P5Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VACTOSERTIB
INN  
Official Name English
vactosertib [INN]
Common Name English
1H-IMIDAZOLE-2-METHANAMINE, N-(2-FLUOROPHENYL)-5-(6-METHYL-2-PYRIDINYL)-4-(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL-
Systematic Name English
N-((4-((1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL)-5-(6-METHYLPYRIDIN-2-YL)-1H-IMIDAZOL-2-YL)METHYL)-2-FLUOROANILINE
Systematic Name English
EW-7197
Common Name English
Vactosertib [WHO-DD]
Common Name English
2-FLUORO-N-((4-(6-METHYLPYRIDIN-2-YL)-5-((1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL)-1H-IMIDAZOL-2-YL)METHYL)ANILINE
Systematic Name English
TEW-7197
Code English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
FDA ORPHAN DRUG 827321
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
NCI_THESAURUS C61074
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
FDA ORPHAN DRUG 767320
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
FDA ORPHAN DRUG 834121
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
FDA ORPHAN DRUG 575617
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
Code System Code Type Description
SMS_ID
300000008774
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
PRIMARY
CAS
1352608-82-2
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
PRIMARY
NCI_THESAURUS
C116357
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
PRIMARY
PUBCHEM
54766013
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
PRIMARY
INN
10645
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
PRIMARY
DRUG BANK
DB15310
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
PRIMARY
FDA UNII
6T4O391P5Y
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
PRIMARY
EPA CompTox
DTXSID401010181
Created by admin on Sat Dec 16 08:23:48 GMT 2023 , Edited by admin on Sat Dec 16 08:23:48 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY